HIMS241101P27000
- 6.80
- 0.000.00%
Hims & Hers Health Newsroom
Earnings Preview: HIMS to Report Financial Results Post-market on November 04
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $25
Hims & Hers Health Options Spot-On: On October 30th, 101.6K Contracts Were Traded, With 290.06K Open Interest
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Reported Earlier, 'Novo Nordisk's Ozempic and Wegovy, Long in Shortage, Are Now Listed as Available by FDA; It Remains Unclear How the Update Could Affect Patients as Well as Compounders' - STAT News
Smart Money Is Betting Big In HIMS Options
12 Health Care Stocks Moving In Wednesday's Intraday Session
Express News | Hims & Hers Reports Outcomes For Weight Loss Program With Compounded Medications, Highlighting 9.3 Lb Average Loss In First Month And 90% Customer Satisfaction With Personalized Dosing
How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals
Leerink Partners Maintains Hims & Hers Health(HIMS.US) With Hold Rating, Raises Target Price to $26
Express News | Google To Launch New "Sexual Health & Wellness" Policy On November 11, Permitting Promotion Of Personal Lubricants And Prescription Drugs In Select Countries
Hims & Hers Health, Inc. (HIMS) Exceeds Market Returns: Some Facts to Consider
Hims & Hers Health Down 9% After Novo Nordisk Lashes Out at Wegovy Copycats
A Look Into Hims & Hers Health Inc's Price Over Earnings
Press Release: Define Ventures Appoints Bruce Broussard as Venture Partner
Unusual Options Activity: CNC, ALK and Others Attract Market Bets, CNC V/OI Ratio Reaches 1571.2
This Is What Whales Are Betting On Hims & Hers Health
Express News | Hims & Hers Names DR. Jessica Shepherd as Chief Medical Officer of Hers
In-Depth Examination Of 6 Analyst Recommendations For Hims & Hers Health